McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a November 30, 2012 edition of BioWorld.com in an article entitled, “Biotechs Urged to Weigh in as Supreme Court Considers Myriad.” The U.S. Supreme Court will examine the patentability of human genes in a case focusing on the biotech’s patents for isolated DNA of the BRCA 1 and BRCA 2 genes used in its diagnostics for breast and ovarian cancers. When Myriad came before the Supreme Court earlier this year, the justices remanded the case to the Federal Circuit with instructions to reconsider it in light of the high court’s Mayo v. Prometheus ruling a week earlier. View the article